{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "STX.L",
  "generated_at": "2026-01-17T11:51:30.454773Z",
  "top_card": {
    "ticker": "STX.L",
    "company_name": "Shield Therapeutics plc",
    "sector": "Healthcare",
    "market_cap_gbp": 130275044,
    "days_active": 550,
    "apex_score_100": 60,
    "confidence_score_100": 40,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "CROWDED",
    "action": "SELL/TAKE_PROFITS",
    "thesis_one_liner": "SELL/TAKE_PROFITS - CROWDED timing with 60/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Shield Therapeutics plc",
      "sector": "Healthcare",
      "industry": "Drug Manufacturers - Specialty & Generic",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 130275044,
      "current_close_price": 12.2
    },
    "basics": {
      "ticker": "STX.L",
      "current_price": 12.2,
      "ath": 184.8142,
      "atl": 1.063,
      "ath_date": "2020-01-08",
      "atl_date": "2024-04-25",
      "week_52_high": 12.5,
      "week_52_low": 2.1,
      "week_52_high_date": "2025-12-04",
      "week_52_low_date": "2025-04-17",
      "drawdown_from_ath_pct": 93.4,
      "data_start": "2020-01-02",
      "data_end": "2026-01-16",
      "total_bars": 1526
    },
    "latest_signal": {
      "date": "2024-07-15",
      "scan_date": "2026-01-14",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 1.6,
      "drawdown_pct": 87.55,
      "ai_score": 9.0,
      "rsi": 18.2,
      "cycle_position": 0.1818,
      "holding_period_days": 550,
      "current_pnl_pct": 662.5,
      "rally_state": "peaked",
      "distance_from_high_pct": -0.37,
      "Rally_Count": 1,
      "days_since_last_high": 27,
      "last_high_date": "2025-12-18",
      "lock_in_reached": true,
      "lock_in_date": "2025-12-03",
      "best_rally_pct": 637.5
    },
    "best_historical_signal": {
      "signal_date": "2024-04-25",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "entry_price": 1.225,
      "peak_price": 12.5,
      "peak_date": "2025-12-04",
      "rally_pct": 920.41,
      "days_to_peak": 588,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "STX.L_2022-06-30",
        "signal_date": "2022-06-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.2857,
        "current_price": 11.756,
        "current_return_pct": 61.36,
        "best_rally_pct": 75.33,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 9,
        "distance_from_high_pct": -7.97,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1294,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-01",
        "signal_date": "2022-07-01",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 11.756,
        "current_return_pct": 56.15,
        "best_rally_pct": 69.68,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -7.97,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1293,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-04",
        "signal_date": "2022-07-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.5085,
        "current_price": 11.756,
        "current_return_pct": 80.63,
        "best_rally_pct": 96.27,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 9,
        "distance_from_high_pct": -7.97,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1290,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-05",
        "signal_date": "2022-07-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.3628,
        "current_price": 11.756,
        "current_return_pct": 84.76,
        "best_rally_pct": 100.76,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 6,
        "distance_from_high_pct": -7.97,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1289,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-08",
        "signal_date": "2022-07-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.2414,
        "current_price": 11.756,
        "current_return_pct": 88.36,
        "best_rally_pct": 104.67,
        "best_rally_date": "2022-09-07",
        "rally_state": "rallying",
        "Rally_Count": 5,
        "distance_from_high_pct": -7.97,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1286,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-27",
        "signal_date": "2022-10-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 11.756,
        "current_return_pct": 56.15,
        "best_rally_pct": 66.04,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 7,
        "distance_from_high_pct": -5.95,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1175,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-28",
        "signal_date": "2022-10-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.2857,
        "current_price": 11.756,
        "current_return_pct": 61.36,
        "best_rally_pct": 71.57,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -5.95,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1174,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-31",
        "signal_date": "2022-10-31",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 11.756,
        "current_return_pct": 56.15,
        "best_rally_pct": 66.04,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 7,
        "distance_from_high_pct": -5.95,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1171,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-13",
        "signal_date": "2022-12-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.8,
        "current_price": 11.756,
        "current_return_pct": 72.88,
        "best_rally_pct": 83.82,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 9,
        "distance_from_high_pct": -5.95,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1128,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-14",
        "signal_date": "2022-12-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9214,
        "current_price": 11.756,
        "current_return_pct": 69.85,
        "best_rally_pct": 80.6,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -5.95,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1127,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-19",
        "signal_date": "2022-12-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9,
        "current_price": 11.756,
        "current_return_pct": 70.38,
        "best_rally_pct": 81.16,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -5.95,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1122,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2023-01-05",
        "signal_date": "2023-01-05",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.6,
        "current_price": 11.756,
        "current_return_pct": 78.12,
        "best_rally_pct": 89.39,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -5.95,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1105,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2023-01-06",
        "signal_date": "2023-01-06",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.5,
        "current_price": 11.756,
        "current_return_pct": 80.86,
        "best_rally_pct": 92.31,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -5.95,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 1104,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-02-27",
        "signal_date": "2024-02-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.42,
        "current_price": 11.756,
        "current_return_pct": 385.79,
        "best_rally_pct": 387.6,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 4,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 687,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-02",
        "signal_date": "2024-04-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.0,
        "current_price": 11.756,
        "current_return_pct": 487.8,
        "best_rally_pct": 490.0,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 3,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 652,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-03",
        "signal_date": "2024-04-03",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.9,
        "current_price": 11.756,
        "current_return_pct": 518.74,
        "best_rally_pct": 521.05,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 3,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 651,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-04",
        "signal_date": "2024-04-04",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.775,
        "current_price": 11.756,
        "current_return_pct": 562.31,
        "best_rally_pct": 564.79,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 3,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 650,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-05",
        "signal_date": "2024-04-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 11.756,
        "current_return_pct": 591.53,
        "best_rally_pct": 594.12,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 2,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 649,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-08",
        "signal_date": "2024-04-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 11.756,
        "current_return_pct": 591.53,
        "best_rally_pct": 594.12,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 2,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 646,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-09",
        "signal_date": "2024-04-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.65,
        "current_price": 11.756,
        "current_return_pct": 612.48,
        "best_rally_pct": 615.15,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 2,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 645,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-12",
        "signal_date": "2024-04-12",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.525,
        "current_price": 11.756,
        "current_return_pct": 670.89,
        "best_rally_pct": 673.77,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 2,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 642,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-16",
        "signal_date": "2024-04-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.525,
        "current_price": 11.756,
        "current_return_pct": 670.89,
        "best_rally_pct": 673.77,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 2,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 638,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-17",
        "signal_date": "2024-04-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.48,
        "current_price": 11.756,
        "current_return_pct": 694.32,
        "best_rally_pct": 697.3,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 2,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 637,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-25",
        "signal_date": "2024-04-25",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.225,
        "current_price": 11.756,
        "current_return_pct": 859.67,
        "best_rally_pct": 863.27,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 1,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 629,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-26",
        "signal_date": "2024-04-26",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.35,
        "current_price": 11.756,
        "current_return_pct": 770.81,
        "best_rally_pct": 774.07,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 1,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 628,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-29",
        "signal_date": "2024-04-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 11.756,
        "current_return_pct": 770.81,
        "best_rally_pct": 774.07,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 1,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 625,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-30",
        "signal_date": "2024-04-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 11.756,
        "current_return_pct": 770.81,
        "best_rally_pct": 774.07,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 1,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 624,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-07-15",
        "signal_date": "2024-07-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.6,
        "current_price": 11.756,
        "current_return_pct": 634.75,
        "best_rally_pct": 637.5,
        "best_rally_date": "2025-12-03",
        "rally_state": "peaked",
        "Rally_Count": 1,
        "distance_from_high_pct": -0.37,
        "days_since_last_high": 27,
        "lock_in_reached": true,
        "age_days": 548,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 28,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 411.07,
      "median_rally_pct": 470.76,
      "best_rally_pct": 920.41,
      "worst_rally_pct": 70.68
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-17 01:26:38 UTC",
    "volatility": {
      "atr_normalized": 8.18,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "TOPPED_OUT"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 60/100 indicates strong opportunity quality",
      "Timing regime: CROWDED",
      "Historical profile: 1 rallies, 638% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "STX.L",
      "latest": [
        {
          "title": "ACCRUFeR receives Authorisation by Korean Ministry",
          "announcement_date": "7th Nov 2025",
          "release_time": "7:03 am",
          "source": "RNS",
          "content": "7 Nov 2025 07:03\nRNS Number : 6560G\nShield Therapeutics PLC\n07 November 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nACCRUFeR\u00ae receives Marketing Authorisation by Korean Ministry of Food and Drug Safety (MFDS)\nLondon, UK, 07 November 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company focused on addressing iron deficiency, is pleased to announce that the Korean Ministry of Food and Drug Safety (MFDS) has granted regulatory approval for ACCRUFeR\u00ae (Ferric Maltol) in the Republic of Korea (South Korea) for the treatment of iron deficiency in adult subjects.\nThis approval is an important milestone and follows the successful completion of a pharmacokinetic (PK) study which confirmed that the absorption of iron from ACCRUFeR\u00ae was comparable between patients in South Korea and the patient population enrolled in the key clinical studies supporting ACCRUFeR\u00ae effectiveness and safety and the subsequent submission of a New Drug Application (NDA) by Korea Pharma (\"KP\") in 2024. This approval marks a significant step forward in expanding access to ACCRUFeR\u00ae for patients in South Korea suffering from iron deficiency.\nShield is eligible to receive payments upon the first sale, as well as performance-based sales milestones and royalties on net sales of ACCRUFeR\u00ae in South Korea.\nAnders Lundstrom, Chief Executive Officer, commented\n:\nWe are delighted with this approval of ACCRUFeR\u00ae in South Korea and commend Korea Pharma for their dedication and expertise throughout the regulatory process. This achievement reinforces our commitment to making ACCRUFeR\u00ae available to patients globally and highlights the strength of our international partnerships. Shield looks forward to supporting Korea Pharma in the commercial launch of ACCRUFeR\u00ae in South Korea and continuing its mission to improve the lives of patients with iron deficiency worldwide.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today for ID/IDA (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nKorea ID/IDA Market\nThere are currently 5.2M people in Korea living with ID/IDA as\nstated in the 'Prevalence and risk factors for iron deficiency anemia in the Korean population: results of the fifth Korea National Health and Nutrition Examination Survey'.\nAbout Korea Pharma Co.,Ltd\nKorea Pharma is a prescription pharmaceutical company focusing on CNS (central nervous system) and GI (gastro-intestinal) products. Korea Pharma has previously signed an exclusive distribution agreement\nW\nith Norgine BV, a global PEG-based bowel cleansing agent development company, for d\nistribution of PLENVU\n\u00ae\n,\nthe world's first one-litre PEG (\npolyethylene glycol)\nbowel preparation drug, and is developing a liquid type PEG laxative.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nREAEAKFXESNSFEA"
        },
        {
          "title": "RetailBook Offer",
          "announcement_date": "6th Dec 2024",
          "release_time": "11:31 am",
          "source": "RNS",
          "content": "6 Dec 2024 11:31\nRNS Number : 1732P\nShield Therapeutics PLC\n06 December 2024\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.\nTHE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAILBOOK OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF SHIELD THERAPEUTICS PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF SHIELD THERAPEUTICS PLC.\n6 December 2024\nShield Therapeutics plc\n(\"\nShield\n\" or the \"\nCompany\n\")\nRetailBook Offer\n\u00b7\nShield is pleased to announce a conditional RetailBook Offer of new ordinary shares of 1.5p each in the capital of the Company (\"\nOrdinary Shares\n\") via\nRetailBook\n(the \"\nRetailBook Offer Shares\n\")\n;\n\u00b7\nThe offer price for each new RetailBook Offer Share is\n3.0\np per share (the\n\"Offer Price\")\n, representing a premium of 5.3 per cent to the closing mid-price of the Company's existing Ordinary Shares on 5 December 2024;\n\u00b7\nInvestors can take part through RetailBook's partner network of participating retail brokers, wealth managers and investment platforms, which includes AJ Bell, Hargreaves Lansdown and interactive investor;\n\u00b7\nApplications for RetailBook Offer Shares through these partners can be made from tax efficient savings vehicles such as ISAs or SIPPs, as well as General Investment Accounts (\"\nGIAs\n\");\n\u00b7\nThe RetailBook Offer is available to existing shareholders only;\n\u00b7\nThere is a minimum subscription of \u00a350 per investor in the RetailBook Offer;\n\u00b7\nA maximum of\n33,333,333\nRetailBook Offer Shares will be issued and accordingly, the maximum gross proceeds of the RetailBook Offer are\n\u00a31,000,000\n\u00b7\nThe RetailBook Offer is expected to close at\n4.30 p.m.\non\n20 December\n2024;\n\u00b7\nCompletion of the RetailBook Offer is conditional on the completion of the Subscription and admission of the RetailBook Offer Shares to trading on AIM;\n\u00b7\nNo commission will be charged by RetailBook on applications to the RetailBook Offer.\nThe RetailBook\nOffer\nShield is pleased to announce a conditional RetailBook Offer for of new\nRetailBook Offer Shares\nvia RetailBook (the \"\nRetailBook Offer\n\")\nat an Offer Price of\n3.0\np per RetailBook Share, being a premium of 5.3 per cent to the closing mid-price of the Company's existing Ordinary Shares on 5 December 2024.\nEarlier today the Company also announced a conditional subscription for new Ordinary Shares (the \"\nSubscription Shares\n\") by its existing shareholder, AOP Health International Management AG (\"\nAOP\n\") (the \"\nSubscription\n\"). For the avoidance of doubt, the RetailBook Offer is not part of the Subscription.\nThe issue of the RetailBook Offer Shares will be conditional upon completion of the Subscription and will be undertaken pursuant to the authorities granted to the Directors at the Company's Annual General Meeting held on 20 June 2024. The issue of the Subscription Shares is conditional on the passing of all resolutions relating to the Subscription (the \"\nResolutions\n\") at a general meeting of the Company to be held at Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle NE8 3DF at 09:30 a.m. on 24 December 2024 (the \"\nGeneral Meeting\n\") and the admission of the Subscription Shares to trading on AIM.\nSubject to the Resolutions being passed at the General Meeting, it is expected that the Subscription Shares and such number of RetailBook Offer Shares as are subscribed for will be admitted to trading on AIM at 8.00 a.m. on 30 December 2024.\nReason for the RetailBook\nOffer\nThe Company values its retail shareholder base and believes that it is in the best interests of shareholders as well as wider stakeholders, to provide\nits existing retail shareholders\nin the United Kingdom, the opportunity to participate in the RetailBook Offer.\nThe RetailBook Offer is open to existing shareholders of the Company who are eligible investors in the United Kingdom following release of this announcement. The RetailBook Offer is expected to close at 4.30 p.m. on 20 December 2024 and may close earlier at the discretion of the Company or if it is oversubscribed.\nInvestors can participate through RetailBook's partner network of investment platforms, retail brokers and wealth managers, subject to such partners' participation. Participating partners include:\n\u00b7\nAJ Bell;\n\u00b7\nHargreaves Lansdown; and\n\u00b7\ninteractive investor\nApplications for RetailBook Offer Shares through participating partners can be made from tax efficient savings vehicles such as ISAs or SIPPs, as well as GIAs. Investors wishing to apply using their ISA, SIPP or GIA should contact their investment platform, retail broker or wealth manager for details of their terms and conditions, process and any relevant fees or charges.\nThe RetailBook Offer Shares will, when issued, be credited as fully paid and will rank\npari passu\nin all respects with existing Ordinary Shares including the right to receive all dividends and other distributions declared, made or paid after their date of issue.\nEligibility for the RetailBook\nOffer\nThe RetailBook Offer is available to existing shareholders of Shield only. To be eligible to participate in the RetailBook Offer, applicants must be a customer of a participating intermediary and, as at the date hereof, must be a shareholder in the Company.\nEligible investors wishing to subscribe for RetailBook Offer Shares should contact their investment platform, retail broker or wealth manager to confirm if they are participating in the RetailBook Offer.\nThere is a minimum subscription of \u00a350 per investor. The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries including relevant commission or fee charges. Note, no commission will be charged to investors by RetailBook in connection with the RetailBook Offer.\nThe Company reserves the right to scale back any order under the RetailBook Offer at its discretion. The Company reserves the right to reject any application for subscription under the RetailBook Offer without giving any reason for such rejection.\nIt is important to note that once an application for RetailBook Offer Shares has been made and accepted via an intermediary, it cannot be withdrawn. Investors should also note that the RetailBook Offer will remain open alongside a live share price and the market price of the shares may be less than the Offer Price.\nIt is a term of the RetailBook Offer that the aggregate value of the shares available for subscription at the Offer Price does not exceed \u00a31,000,000.\nInvestors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.\nIt should be noted that a subscription for RetailBook Offer Shares and investment in the Company carries a number of risks. Investors should take independent advice from a person experienced in advising on investment in securities such as the RetailBook Offer Shares if they are in any doubt.\nAn investment in the Company will place capital at risk. The value of your investment in the Company and any income from it is not guaranteed and can go down as well as rise due to stock market and currency movements. When you sell your investment, you may get back less than the amount originally invested.\nNeither past performance nor any forecasts should be considered a reliable indicator of future results.\nThis announcement should be read in its entirety. In particular, the information in the \"Important Notices\" section of the announcement should be read and understood.\nEnquiries\nShield Therapeutics plc\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nRetailBook\nKit Atkinson / Michael Ward\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\nT: +44 (0) 191 511 8500\nInfo@retailbook.com\nT: +44 (0)20 7418 8900\nFurther information on the Company can be found on its website at\nwww.shieldtherapeutics.com\nImportant Notices\nThis announcement has been prepared by, and is the sole responsibility of, the Company.\nThe RetailBook Offer is offered in the United Kingdom under the exemption from the requirement to publish a prospectus in section 86(1)(e) of FSMA. As such, there is no need for publication of a prospectus pursuant to the Prospectus Regulation Rules of the Financial Conduct Authority, or for approval of the same by the Financial Conduct Authority. The RetailBook Offer is not being made into any jurisdiction other than the United Kingdom.\nNo offering document, prospectus or admission document has been or will be prepared or submitted to be approved by the Financial Conduct Authority (or any other authority) in relation to the RetailBook Offer, and investors' commitments will be made solely on the basis of the information contained in this announcement and information that has been published by or on behalf of the Company prior to the date of this announcement by notification to a Regulatory Information Service in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, the Market Abuse Regulation (EU Regulation No. 596/2014) (\"\nMAR\n\") and MAR as it forms part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018 (as amended).\nThis announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the \"\nUnited States\n\" or \"\nUS\n\")), Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.\nThe RetailBook Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the \"\nUS Securities Act\n\") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States. No public o\ufb00ering of the RetailBook Offer Shares is being made in the United States. The RetailBook Offer Shares are being o\ufb00ered and sold outside the United States in \"o\ufb00shore transactions\", as de\ufb01ned in, and in compliance with, Regulation S under the US Securities Act. In addition, the Company has not been, and will not be, registered under the US Investment Company Act of 1940, as amended.\nThis announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for RetailBook Offer Shares in the United States, Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction in which such offer or solicitation is or may be unlawful. No public offer of the securities referred to herein is being made in any such jurisdiction.\nThe distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.\nRetailBook is a proprietary technology platform owned and operated by Retail Book Limited (registered address at 10 Queen Street Place, London EC4R 1AG; FRN 994238). Retail Book Limited (\"\nRetailBook\n\") is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company and for no-one else and will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the RetailBook Offer and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in connection with the RetailBook Offer, admission of the RetailBook Offer Shares to trading on AIM and the other arrangements referred to in this announcement.\nThe value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.\nThe information in this announcement is for background purposes only and does not purport to be full or complete. None of RetailBook or any of its affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. RetailBook and its affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.\nNeither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The RetailBook Offer Shares to be issued or sold pursuant to the RetailBook Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.\nIt is further noted that the RetailBook Offer is only open to investors in the United Kingdom who fall within Article 43 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes an existing member of the Company).\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOEBGBDDLUGDGSL"
        },
        {
          "title": "Subscription by AOP Health to raise US$10 million",
          "announcement_date": "6th Dec 2024",
          "release_time": "11:30 am",
          "source": "RNS",
          "content": "6 Dec 2024 11:30\nRNS Number : 1764P\nShield Therapeutics PLC\n06 December 2024\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\",\nthe\u00a0\"Group\"\u00a0or the\u00a0\"Company\")\nSubscription by AOP Health International Management AG of 256,410,256 Ordinary Shares at 3.0p per share to raise US$10 million\nRetailBook Offer of up to 33,333,333 Ordinary Shares to raise up to \u00a31.0 million\nProposed waiver of obligations under Rule 9 of the Takeover Code\nand\nNotice of General Meeting\nLondon, UK, 6 December 2024:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, today announces, further to the announcements on 29 October 2024 and 21 November 2024, a subscription by AOP for Ordinary Shares at a subscription price of 3.0 pence per Ordinary Share (the \"Subscription Price\") to raise aggregate gross proceeds of $10 million (the \"Subscription\"). The Company entered into a subscription agreement with AOP on 6 December 2024 pursuant to which AOP conditionally agreed to subscribe for 256,410,256 new Ordinary Shares at the Subscription Price (the \"Subscription Agreement\").\nSeparately, and conditional on completion of the Subscription, the Company is undertaking an intermediaries offer via RetailBook of up to 33,333,333 new Ordinary Shares at the Issue Price to existing retail shareholders of the Company (the \"RetailBook Offer\").\nAOP has stated to the Company that it is not prepared to proceed with an equity investment in the Company unless it obtains a controlling interest (i.e. greater than 50% of the Enlarged Share Capital) as a result. Such a Subscription is conditional upon the approval of the Resolutions by the Shareholders at the General Meeting (including the Waiver Resolution) and the Subscription Admission. If such approvals are not provided, AOP will not be required to proceed with an equity investment in the Company resulting in the Company not receiving the aggregate gross proceeds of at least $10 million, which would otherwise have helped the Company achieve its aim of becoming cash flow positive by the end of the calendar year of 2025.\nAOP (excluding its concert parties) currently holds\n311,597,265\nOrdinary Shares, representing 39.84 per cent. of the Company's issued share capital. The AOP Directors and persons acting in\nconcert with AOP currently hold, in aggregate, 327,873,978\nOrdinary Shares, representing 41.93 per cent. of the Company's issued share capital.\nIn the event that the maximum number of RetailBook Offer Shares are issued, following the completion of the Subscription, AOP (excluding its concert parties) will hold 568,007,521 Ordinary Shares, representing 53.00 per cent. of the Enlarged Share Capital, and AOP, the AOP Directors and its concert parties will hold 584,284,234 Ordinary Shares in aggregate, representing 54.51 per cent. of the Enlarged Share Capital.\nIn the event no RetailBook Offer Shares are issued, following the Subscription, AOP (excluding its concert parties) would hold 568,007,521 Ordinary Shares, representing approximately 54.70 per cent. of the Enlarged Share Capital, and AOP, the AOP Directors and persons acting in\nconcert with AOP would hold 584,284,234\nOrdinary Shares, representing approximately 56.26 per cent. of the Enlarged Share Capital.\nThe proposed Subscription gives rise to certain considerations under the Takeover Code.\nUnder Rule 9 of the Takeover Code, when any person who, together with persons acting in concert with that person, is interested in shares which in the aggregate carry not less than 30 per cent. of the voting rights of a company, but does not hold shares carrying more than 50 per cent. of such voting rights, and such person, or any person acting in concert with that person, acquires an interest in any other shares which increases the percentage of the shares carrying voting rights in which that person is interested, then, that person is normally required to extend offers in cash for all the remaining equity share capital of the company (a \"Mandatory Offer\").\nAOP has confirmed that it is not prepared to make a Mandatory Offer for the Company. The Panel has agreed to grant the Panel Waiver on condition that the Waiver Resolution is passed by the Independent Shareholders at the General Meeting on a poll vote. The Subscription is conditional upon the Waiver Resolution being passed.\nIn accordance with the provisions of the Takeover Code, AOP and each member of its concert party is considered to be interested in the outcome of the Waiver Resolution and, accordingly, each of them will not vote on the Waiver Resolution. Dr Christian Schweiger and Dr Rudolf Widmann have not taken part in any decision of the Independent Directors relating to the Panel Waiver.\nThe Directors do not have sufficient authorities to allot the Subscription Shares to AOP pursuant to the Subscription. Accordingly, the Subscription is also conditional upon the Directors obtaining appropriate Shareholder authorities at the General Meeting to allot the Subscription Shares to AOP and to disapply statutory pre-emption rights which would otherwise apply to such allotment.\nThe issue of the RetailBook Offer Shares will be conditional upon completion of the Subscription and will be undertaken pursuant to the authorities granted to the Directors at the Company\u2019s Annual General Meeting held on 20 June 2024.\nSubject to the Resolutions being passed at the General Meeting, it is expected that the Subscription Shares and the Issued RetailBook Offer Shares will be admitted to trading on AIM at 8.00 a.m. on 30 December 2024. Further details regarding the Subscription and the RetailBook Offer are set out at paragraphs 4 and 8 below.\nA circular, including notice of the General Meeting, is expected to be sent to Shareholders and be made available on the Company's website at\nhttps://www.shieldtherapeutics.com/\non or around 6 December 2024 (the \u201cCircular\u201d). This announcement and the Circular explain the background to the Subscription and the RetailBook Offer, to set out the reasons why the Independent Directors believe that the Subscription and the Panel Waiver are in the best interests of the Company and its Shareholders as a whole, and to seek Shareholder approval of the Resolutions at the General Meeting, which will be held at Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle NE8 3DF at 09:30 am on 24 December 2024.\nIMPORTANT NOTICE\nThe Company has called the General Meeting in order to put to Shareholders the Resolutions required to approve the Panel Waiver and to complete the Subscription.\nIf the Resolutions are not approved by Shareholders at the General Meeting, no Ordinary Shares will be issued to AOP pursuant to the Subscription or to retail investors pursuant to the RetailBook Offer, and neither the Subscription nor RetailBook Offer will proceed. As such, the anticipated net proceeds of the Subscription and the RetailBook Offer would not be received by the Company. Alternative funding may not be available to Shield on suitable terms or at all, as expanded on below.\nThe Company\u2019s ability to raise additional debt financing is limited by an existing $20 million secured debt financing facility with SWK, as well as a recently expanded $15 million factoring arrangement between Shield US and Sallyport. In addition, in July 2024 the Company entered into a $5.7 million milestone monetization agreement with AOP to raise additional capital to support the Company\u2019s growth. The Company has therefore continued to source significant capital in addition to a number of equity raises completed since 2021 to finance anticipated growth in the US. It has recently become clear to the Board that additional capital is needed to help the Company achieve its aim of becoming cash flow positive by the end of the calendar year of 2025.\nIf the Company was not able to obtain additional funding, the Independent Directors believe the Group would only have sufficient working capital to trade through to approximately Q2 of 2025. Shield\u2019s rate of cash burn, and its ability to meet the covenants under the SWK facility, remain highly dependent on the rate of sales growth for ACCRUFeR\u00ae.\n2. Background to and reasons for the Subscription\nThe Company confirmed its intention to self-commercialise ACCRUFeR\u00ae in the US in 2020 and since that time it has made significant progress towards creating a successful commercial entity in the US, which is a key market globally for pharmaceutical companies. Supporting this commercial strategy has required significant capital, and the Company has raised over \u00a350 million in equity since early 2021 and has also sought additional types of capital at various times including a convertible loan from AOP, $20 million of debt funding from SWK, a $15 million factoring arrangement between Shield US and Sallyport and, more recently, $5.7 million from a milestone monetization agreement with AOP. This capital has enabled the Company to materially grow its revenues from the sale of ACCRUFeR\u00ae in the US, with Q3 2024 revenues being $7.2million compared to $1.2 million in Q1 2023. Total Group revenues in the nine-month period to 30 September 2024 equated to $20 million, of which around $18.2 million were earned in the US.\nFor some time, the Board has been focused on the Group becoming cash flow positive by the end of the calendar year of 2025. As announced by the Company on 29 October 2024, following analysis of the Q3 2024 ACCRUFeR\u00ae performance and assessing the consequential impact on its internal projections, the Board concluded that additional capital would be required and also confirmed that measures to lower the Group\u2019s operating cost base would be taken to help the Company achieve its goal of becoming cash flow positive by the end of 2025. At the same time, Shield US agreed an expansion of its working capital financing with Sallyport from $10 million to $15 million and confirmed that, based on the Company's internal estimates at the time, the Group had a cash runway into Q2 2025. The Company's largest shareholder, AOP, executed a non-binding term sheet at the same time to subscribe for new Ordinary Shares at a subscription price of 4.0 pence per Ordinary Share, which would raise aggregate gross proceeds of at least $10 million. The 4.0 pence price represented a 5.3% premium to the closing middle market price of an Ordinary Share on 28 October 2024. Based on the Company's internal estimates, the Subscription would help the Company achieve its aim of becoming cash flow positive by the end of the calendar year of 2025. The Company's rate of cash burn and anticipated cash runway are highly dependent on sales growth for ACCRUFeR\u00ae achieving the Company\u2019s internal forecasts.\nFollowing the announcement on 29 October 2024, the Company\u2019s share price has declined and on the Disclosure Date, the closing middle market price of an Ordinary Share was 2.85 pence. AOP and the Company have therefore agreed to a subscription price of 3.0p per Subscription Share with AOP, representing a 5.3 per cent. premium to the closing middle market price on the Disclosure Date. The gross proceeds of the Subscription will remain at $10,000,000.\nPrior to the announcement on 29 October 2024, the Company had assessed a limited range of options to raise additional capital, however, no feasible such options were identified. As detailed above,\nthe Company\u2019s ability to raise additional debt financing is limited by its existing $20 million secured debt financing facility with SWK, as well as a recently expanded $15 million factoring arrangement between Shield US and Sallyport. In addition, in July 2024 Shield entered into a $5.7 million milestone monetization agreement with AOP to raise additional capital to support the Company\u2019s growth. Finally, market conditions for small cash burning companies quoted on AIM remain challenging and, accordingly, the Company and its brokers have not been able to source additional equity capital on terms more favourable than those being proposed by AOP in connection with the Subscription.\nThe Board continues to see a significant opportunity for the generation of Shareholder value in the future and the Subscription is intended to provide the Company with the additional capital needed to help the Company achieve its aim of becoming cash flow positive by the end of 2025.\nThe Board notes AOP's statement that AOP does not have any intention of changing the composition of the Board before the Company's 2026 Annual General Meeting. However, depending upon the progress made with commercialising ACCRUFeR\u00ae/Feraccru\u00ae and the Company's financial situation, AOP may decide to exercise its right to do so over the next 12 to 18 months.\n3. Information on the Company\nThe Company is a commercial stage pharmaceutical company specialising in iron deficiency. The Company is focused on\nthe commercialization of\nACCRUFeR\u00ae\n/Feraccru\u00ae (ferric maltol), a novel oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation.\nThe Company launched\nACCRUFeR\u00ae\nin the US in May 2023 following the entry into an exclusive, multi-year collaboration agreement with Viatris, Inc. signed in December 2022. Feraccru\u00ae is commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. The Company also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of\nACCRUFeR\u00ae\n/ Feraccru\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with KYE Pharmaceuticals Inc. for Canada.\nOn 4 September 2024, the Company announced its unaudited interim results for the six months ended 30 June 2024 and provided a business update covering its activities in H1 2024. On 29 October 2024, the Company published an unaudited trading update relating to its activities in Q3 2024, in which it reported:\nTotal ACCRUFeR\u00ae net sales of $7.2 million, representing 4% growth compared to $6.9 million in Q2 2024 and 76% growth compared to Q3 2023;\n2. The growth rate difference between revenues and prescription demand were due to the impact of wholesalers buying ahead of the July 4 weekend during the last week of June 2024;\n3. Total prescriptions of approximately 43,500, an increase of 20% over Q2 2024 and an 86% increase over Q3 2023;\n4. An average net selling price of $167 per prescription vs. $171 in Q2 2024 and $148 in Q3 2023. Excluding July, the average net selling price in Q3 2024 was $192 per prescription;\n5. Total Group revenues of $8.0 million including royalties and milestones from global partners for Q3 2024, resulting in $20.0 million of revenue for the 9 months ended 30 September 2024; and\n6. Cash and cash equivalents of $7.7 million as compared to $8.1 million as at 30 June 2024.\nError! Bookmark not defined.\nThe Board confirmed at that time that its internal estimates indicated that trading remains in line with market expectations for 2024 and the Company is expected to meet the total revenue covenant target of $31.5 million for the full year 2024 under the debt facility agreement with SWK.\nOn 21 November 2024, Shield announced a business update in which it reported:\nRecruitment has recently been completed of adult patients in the Phase 3 confirmatory study in China, being the final study required to support the filing of an NDA in China for the commercialisation of Feraccru\u00ae/Accrufer\u00ae; and\n2. Strong sales of ACCRUFeR\u00ae in October 2024 were driven primarily by an increase net selling price to more than $225 per prescription.\n4. Subscription\nThe Company and AOP entered into the Subscription Agreement on 6 December\n2024 pursuant to which AOP conditionally agreed to subscribe for\n256,410,256\nOrdinary Shares at the Issue Price, raising aggregate proceeds of $10 million. In the event that the maximum number of RetailBook Offer Shares are issued, following the completion of the Subscription, AOP (excluding its concert parties) will hold\n568,007,521\nOrdinary Shares, representing\n53.00\nper cent. of the Enlarged Share Capital, and AOP and its concert parties will hold\n584,284,234\nOrdinary Shares in aggregate, representing\n54.51\nper cent. of the Enlarged Share Capital.\nIn the event that no RetailBook Offer Shares are issued, following the Subscription, AOP (excluding its concert parties) will hold 568,007,521 Ordinary Shares, representing approximately 54.70 per cent. of the Enlarged Share Capital and AOP together with its concert parties will hold 584,284,234 Ordinary Shares representing approximately 56.26 per cent. of the Enlarged Share Capital.\nThe following table sets out the shareholdings of AOP and each member of the concert party as at the date of this announcement and also upon completion of the Subscription under two scenarios: i) there is full take-up under the RetailBook Offer and ii) there is no take-up under the RetailBook Offer:\nShareholder\nShareholding as at the date of this announcement\nPercentage of Existing Ordinary Shares\nNumber of Subscription Shares to be subscribed for\nNumber of Ordinary Shares held post completion of the Subscription\nPercentage of the Enlarged Share Capital if there is full take-up under the RetailBook Offer\nPercentage of the Enlarged Share Capital if there is no take-up under the RetailBook Offer\nAOP\n311,597,265\n39.84\n256,410,256\n568,007,521\n53.00\n54.70\nDr. Christian Schweiger\n11,651,713\n1.49\nNil\n11,651,713\n1.09\n1.12\nDr.\nG\u00fcnther\nKrumpl\n4,000,000\n0.51\nNil\n4,000,000\n0.37\n0.39\nMichael Steiger\n625,000\n0.08\nNil\n625,000\n0.06\n0.06\nTotal\n327,873,978\n41.93\n256,410,256\n584,284,234\n54.51\n56.26\nCompletion of the Subscription is conditional on the passing of the Resolutions at the General Meeting and Subscription Admission. Accordingly, if the Resolutions are not passed at the General Meeting, the Subscription will not proceed and the Company will not receive the proceeds from the Subscription.\nThe Company intends to use the net proceeds of the Subscription to support commercial expansion and\nfor general working capital purposes.\nWhen issued, the Ordinary Shares to be issued pursuant to the Subscription will be fully paid and will rank pari passu\u00a0in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.\nThe Company and AOP entered into the Relationship Agreement to regulate the relationship between the Company and AOP, as the Company's single largest shareholder. The Relationship Agreement contains an undertaking from AOP to abstain from voting on any resolution in relation to any proposed transaction between the Group and the AOP Group. However, for the purposes of the Subscription, the Company has provided AOP with its consent for AOP to vote on Resolutions 2 and 3 at the General Meeting. AOP and its concert party members will not be able to vote on the Waiver Resolution as they are not considered independent.\nIn addition, in connection with the Subscription, the Relationship Agreement has, conditionally on the passing of the Resolutions at the General Meeting and Subscription Admission, been amended and restated to reflect AOP's increased interest in the Company's share capital. The material changes being made to the terms of the Relationship Agreement are set out in the Circular and a copy of the Relationship Agreement will be available on the Company\u2019s website.\n5. Intentions of AOP for the Company following the Subscription\nAOP is committing funds to invest in the Company under the proposed Subscription which will enable the Company to progress its strategy, as described in this announcement and as may be developed over time.\nAOP is a long-term shareholder of the Company and supports the strategic plans of the Board to commercialise ACCRUFeR\u00ae, the Company\u2019s sole product. AOP is especially focused on commercialising ACCRUFeR\u00ae in various geographies, with a particular focus on the US, in order to provide sustainable growth for the product and the Company and to make the Company cash flow positive.\n5.1 Following the Subscription, AOP will be the majority shareholder of Shield. As the majority shareholder of Shield, AOP will have the right to appoint a majority of the members of the Board. AOP does not have any intention of changing the composition of the Board before the Company's 2026 Annual General Meeting. However, depending upon the progress made with commercialising ACCRUFeR\u00ae/Feraccru\u00ae and the Company's financial situation, AOP may decide to exercise its right to do so over the next 12 to 18 months.\nFollowing the date of Subscription Admission, AOP will work alongside the Board to review the business of the Group, with a view to ensuring the ongoing business operations are increasing the Group's revenue and improving its performance. As part of this review, the Board and AOP may also consider whether further capital injections are required and, if so, AOP would only take such actions in accordance with applicable law and the AIM Rules. Whilst there are no new or additional immediate plans regarding changes to Shield's business, some operational and administrative restructuring may be required to help to ensure Shield reaches its revenue aims but neither the Board nor AOP have made any decisions about how such optimization could be carried out, if at all. AOP is committed to supporting Shield\u2019s success and has every intention to act in the best interests of the Company and, in turn, to seek to improve the valuation of the Company for all Shareholders. Assuming the Company performs in line with AOP\u2019s and the Board\u2019s expectations, there is not expected to be any material impact on headcount. However, should the Company fail to meet the Board\u2019s targets, or if AOP determines (acting reasonably) that the Company is underperforming, then it is likely that further restructuring will be required, and this could result in headcount reductions within any of the underperforming business areas (or such other areas as AOP may determine such restructuring is required), which could be material within those businesses and in the context of the Group\u2019s overall headcount.\nAOP has no intention of changing the location of the Group\u2019s headquarters or redeploying the fixed assets of the Group. In addition, AOP does not have any intentions of changing the contributions into the Group\u2019s pension schemes, the accrual of benefits for existing members and the admission of new members. AOP does not have any intentions that would affect the maintenance of the existing trading facilities of the Ordinary Shares on AIM.\nAOP does not plan to make any changes to AOP or any of its subsidiaries following the date of Subscription Admission.\nAOP will use existing cash resources to finance the Subscription. The Subscription will not have a material effect on the earnings, assets or liabilities of AOP.\nAOP has not put in place, and does not intend to put in place, any incentivisation arrangements for the Company\u2019s management in connection with the Subscription.\n6. The City Code on Takeovers and Mergers and the Panel Waiver\nThe Takeover Code is issued and administered by the Panel. The Takeover Code and the Panel operate to ensure fair and equal treatment of shareholders in relation to takeovers, and also provide an orderly framework within which takeovers are conducted. The Takeover Code applies to the Company and as such Shareholders are entitled to the protections afforded by the Takeover Code.\nUnder Rule 9, any person who acquires an interest in shares which, taken together with shares in which that person or any person acting in concert with that person is interested, carry 30 per cent. or more of the voting rights of a company which is subject to the Takeover Code, is normally required to make an offer to all the remaining shareholders to acquire their shares.\nSimilarly, when any person, together with persons acting in concert with that person, is interested in shares which in the aggregate carry not less than 30 per cent. of the voting rights of a company but does not hold shares carrying more than 50 per cent. of the voting rights of the company, an offer will normally be required if such person or any person acting in concert with that person acquires a further interest in shares which increases the percentage of shares carrying voting rights in which that person is interested.\nAn offer under Rule 9 must be in cash at the highest price paid by the person required to make the offer, or any person acting in concert with such person, for any interest in shares of the company acquired during the 12 months prior to the announcement of the offer.\nRule 9 of the Takeover Code further provides, amongst other things, that where any person who, together with persons acting in concert with that person, holds over 50 per cent. of the voting rights of a company and acquires an interest in shares which carry additional voting rights, then they will not normally be required to make a general offer to the other shareholders to acquire their shares. However, the Panel may deem an obligation to make an offer to have arisen on the acquisition by a single member of a concert party of an interest in shares sufficient to increase their individual holding to 30 per cent. or more of a company's voting rights or, if they already hold more than 30 per cent. but less than 50 per cent., an acquisition which increases their shareholdings in that company.\nUnder the Takeover Code, persons acting in concert comprise persons who, pursuant to an agreement or understanding (whether formal or informal), co-operate to obtain or consolidate control of a company or to frustrate the successful outcome of an offer for a company. Control means an interest or interests in shares carrying 30 per cent. or more of the voting rights of the company, irrespective of whether the holding or holdings give de facto control.\nThe Company has agreed with the Panel that AOP and the AOP Directors are acting in concert in relation to the Company.\nAOP (excluding its concert parties) currently holds\n311,597,265\nOrdinary Shares, representing 39.84 per cent. of the Company's issued share capital. AOP, the AOP Directors and persons acting in\nconcert with AOP currently hold, in aggregate, 327,873,978\nOrdinary Shares, representing 41.93 per cent. of the Company's issued share capital. Following the Subscription, assuming the maximum number of RetailBook Offer Shares are issued, AOP (excluding its concert parties) will hold 568,007,521 Ordinary Shares, representing approximately 53.00 per cent. of the Enlarged Share Capital, and AOP, the AOP Directors and persons acting in\nconcert with AOP will hold an aggregate of\n584,284,234\nOrdinary Shares, representing approximately 54.51 per cent. of the Enlarged Share Capital. In the event that no RetailBook Offer Shares are issued, following the Subscription, AOP (excluding its concert parties) will hold 568,007,521 Ordinary Shares, representing approximately 54.70 per cent. of the Enlarged Share Capital and AOP together with its concert parties will hold 584,284,234 Ordinary Shares representing approximately 56.26 per cent. of the Enlarged Share Capital. Therefore, under Rule 9 of the Takeover Code and regardless of the level of take up under the RetailBook Offer, AOP would ordinarily be required to make an offer to all the remaining Shareholders to acquire their Ordinary Shares.\nThe Panel has agreed to waive the obligation to make an offer that would otherwise arise under Rule 9 as a result of the Subscription, subject to the approval of Independent Shareholders\n.\nAccordingly, the Waiver Resolution is being proposed at the General Meeting and will be taken on a poll. The Panel has confirmed that all Shareholders other than AOP and its concert parties will be entitled to vote on the Waiver Resolution. Accordingly, each of AOP and its concert party members will not vote on the Waiver Resolution.\nIn the event the Waiver Resolution is approved and the Subscription proceeds, AOP will not be restricted from making a general offer for the Company. Following Subscription Admission, AOP and its concert party will hold shares carrying more than 50% of the voting rights of the Company and (for so long as they continue to be acting in concert) may accordingly increase their aggregate interests in shares without incurring any obligation to make an offer under Rule 9, although individual members of AOP's concert party will not be able to increase their percentage interests in shares through or between a Rule 9 threshold without Panel consent.\nThe Panel Waiver will be invalidated if any purchases of Existing Ordinary Shares are made by AOP or any of its concert parties in the period between the date of the Circular and the General Meeting.\nFurther details concerning AOP and its concert parties are set out below:\nInformation on AOP\nAOP is a provider of integrated therapy solutions from its operational headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. AOP was founded in 1996 and operates in the field of rare diseases and critical care. The registered office of AOP and the business address of each of the AOP Directors is Industriering 20, 9491 Ruggell, Liechtenstein.\nFor the year ended 31 December 2023, AOP Austria\u2019s consolidated, audited, turnover was EUR 254 million, net assets were EUR 122 million and net income was EUR 24 million. For the year ended 31 December 2022, AOP Austria\u2019s consolidated, audited, turnover was EUR 187 million, net assets were EUR 99 million and net income was EUR 14 million. AOP Austria is a wholly-owned subsidiary of AOP and its concert parties. Since AOP does not have significant assets itself nor does it prepare consolidated financial statements, the consolidated, audited accounts of AOP Austria provide a true and fair representation of the AOP Group.\nAOP employs more than 560 people in 30 countries, including countries in Europe, the United Arab Emirates and Israel. AOP also has multiple strategic partnerships through which it operates internationally.\nAOP focuses on four areas and develops, produces and markets innovative solutions in the treatment areas of Haemato-oncology, Cardiology & Pulmonology, Intensive Care and Neurology.\nAOP does not have any public, current credit rating or outlook from a ratings agency.\nAOP does not plan to make any changes to AOP or any of its subsidiaries if the Subscription completes.\nThe names of the AOP Directors and their positions in AOP are below. Each of Dr. Christian Schweiger and Dr. Rudolf Widmann are also directors of the Company and receive compensation for their positions:\nName\nPosition\nMartin Gst\u00f6hl\nDirector\nDr. G\u00fcnther Krumpl\nDirector\nDr. Rudolf Widmann\nDirector\nDr. Christian Schweiger, MD. PhD\nDirector\nMichael Steiger\nDirector\n7. Irrevocable Undertakings\nEach of the Directors (with the exception of Dr. Rudolf Widmann, who is not a Shareholder) have given irrevocable undertakings to the Company to vote in favour of the Resolutions (excluding, in the case of Dr. Christian Schweiger, in relation to the Waiver Resolution), and to procure that such action is taken by the relevant registered holders, in respect of their beneficial holdings totalling 17,611,441 Ordinary Shares, representing approximately 2.29 per cent. of the Existing Ordinary Shares, to vote in favour of such Resolutions.\nIn addition, AOP has given an irrevocable undertaking to the Company to vote in favour of the Resolutions, other than the Waiver Resolution, and to procure that such action is taken by the relevant registered holders, in respect of AOP's beneficial holdings totalling\n311,597,265\nOrdinary Shares, representing approximately 39.84 per cent. of the Existing Ordinary Shares, to vote in favour of such Resolutions.\n8. Principal terms of the RetailBook Offer\nThe Company has separately agreed to use RetailBook to undertake an intermediaries offer of new Ordinary Shares at the Issue Price, alongside the Subscription, to retail investors through financial intermediaries. For the avoidance of doubt, the RetailBook Offer Shares are not part of the Subscription. Given the shareholder base of the Company, the Directors consider it important to extend the opportunity to invest in the Company at the Issue Price to existing retail shareholders and the Directors have concluded that the RetailBook Offer is the most suitable option available to the Company. The Company intends to conduct an offer for subscription for the RetailBook Offer Shares on the terms of the RetailBook Offer Announcement. The RetailBook Offer is conditional on completion of the Subscription and RetailBook Admission becoming effective no later than 8.00 am on 30 December 2024. The RetailBook Offer may not be fully subscribed. The RetailBook Offer is intended to raise gross proceeds of up to \u00a31.0 million if the maximum number of RetailBook Offer Shares are issued. The Issue Price represents a premium of approximately 5.3 per cent. to the closing middle market price of an Ordinary Share on the Disclosure Date. Pursuant to the terms of the Intermediaries Agreement,the Company will make the RetailBook Offer to retail investors through intermediaries via RetailBook. The obligations of the Intermediaries under the Intermediaries Agreement are conditional in all respects upon: (a) the Subscription becoming unconditional; and (b) RetailBook Admission.\nEach of the Subscription and the RetailBook Offer are separate and distinct transactions involving the issue of new Ordinary Shares. However, the RetailBook Offer is conditional on the Subscription and will not be implemented independently if for any reason the Subscription lapses. The Subscription is not conditional upon the RetailBook Offer.\nNeither AOP nor any of its concert parties will participate in the RetailBook Offer.\n9. Independent Advice\nThe Takeover Code requires the Directors to obtain competent independent advice regarding the merits of the Subscription and the Panel Waiver. Peel Hunt has provided formal advice to the Directors regarding the Subscription and in providing such advice, Peel Hunt has taken into account the Directors\u2019 commercial assessments, as well as the confirmations of AOP's future intentions expressed in paragraph 5 above.\nPeel Hunt confirms that it, and any person who is or is presumed to be acting in concert with it, is independent of AOP and has no personal, financial or commercial relationship, or arrangements or understandings with AOP.\nPeel Hunt has given and has not withdrawn its written consent to the inclusion in this announcement of its name and the references to it in the form and context in which they are included.\n10. Admission, settlement, dealings and total voting rights\nThe Subscription Shares to be issued to AOP pursuant to the Subscription will, when issued, be fully paid up and will rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid on or in respect of the Ordinary Shares after the date of issue of the Subscription Shares, and will on issue be free of all claims, liens, charges, encumbrances and equities.\nAny RetailBook Offer Shares that may be issued pursuant to the RetailBook Offer will, when issued, be fully paid up and will rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid on or in respect of the Ordinary Shares after the date of issue of the Issued RetailBook Shares, and will on issue be free of all claims, liens, charges, encumbrances and equities.\nApplication will be made to the London Stock Exchange for the admission of the Subscription Shares and of the Issued RetailBook Offer Shares to trading on AIM. Admission of the Subscription Shares and of the Issued RetailBook Offer Shares to trading on AIM is expected to occur at 8.00 a.m. on\n30\nDecember 2024\n.\nFollowing Subscription Admission and RetailBook Admission, the total number of Ordinary Shares in the capital of the Company in issue would be 1,071,799,957\n(assuming the maximum number of RetailBook Offer Shares are issued)\nwith each Ordinary Share carrying the right to one vote.\n11. General Meeting\nThe Company has called the General Meeting in order to (i) put to Independent Shareholders the Waiver Resolution required to approve the Panel Waiver and to (ii) put to Shareholders the other Resolutions set out in the notice of the General Meeting at the end of the Circular. All of the Resolutions must be passed by Shareholders at the General Meeting in order for the Subscription to proceed.\nThe notice of General Meeting, which is proposed to be held at\nNorthern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle NE8 3DF at 09:30 am\non 24 December 2024, will be set out at the end of the Circular.\nAt the General Meeting the following Resolutions will be proposed:\nResolution 1 \u2013 Waiver Resolution\nThe Waiver Resolution will be proposed as an ordinary resolution to approve the Panel Waiver. If passed it will approve the Panel Waiver and will allow the issue of the Subscription Shares to AOP without AOP being required to make a Mandatory Offer. The Takeover Code requires the Waiver Resolution to be voted on by the Independent Shareholders only.\nResolution 2 \u2013 Authority to allot shares\nResolution 2 is an ordinary resolution to authorise the Directors to allot relevant securities pursuant to the Subscription with an aggregate nominal value of up to \u00a33,846,154, being equal to\n256,410,256\nnew Ordinary Shares.\nResolution 3 \u2013 Disapplication of statutory pre-emption rights\nResolution 3, which is conditional on the passing of Resolution 2, is a special resolution to authorise the Directors to allot\nnew Ordinary Shares for cash on a non-pre-emptive basis pursuant to the Subscription.\nThe authorities given by the Resolutions 2 and 3 will be in addition to any existing authorities which the Directors already have.\n12. Importance of the Vote and Recommendation\nError! Bookmark not defined.\nShareholders should be aware that, if the Resolutions are not approved at the General Meeting, the Subscription and the RetailBook Offer will not occur and none of the net proceeds of the Subscription or the RetailBook Offer will be received by the Company.\nAlternative funding may not be available to Shield on suitable terms or at all.\nIf the Company was not able to obtain additional funding, the Group would only have sufficient working capital to trade through to approximately Q2 of 2025. Shield\u2019s rate of cash burn remains highly dependent on the rate of sales growth of ACCRUFeR\u00ae in the US.\nAIM Rule 13 Fair and Reasonable Opinion\nThe Subscription constitutes a related party transaction pursuant to Rule 13 of the AIM Rules. The Independent Directors, having consulted with Peel Hunt, consider that the terms of the Subscription are fair and reasonable insofar as Shareholders are concerned. Accordingly, the Independent Directors unanimously recommend that Shareholders vote in favour of the of Resolutions numbered 2 and 3 to be proposed at the General Meeting.\nTakeover Code Fair and Reasonable Opinion\nThe Independent Directors have noted AOP's statement that it is not prepared to proceed with an equity investment in the Company unless it obtains a controlling stake as a result. The Independent Directors have also carefully considered the statements of AOP's future intentions expressed in paragraph 5 above and the Company's need for additional capital and the absence of alternative feasible sources of capital.\nThe Independent Directors, having been so advised by Peel Hunt, consider the terms of the Panel Waiver and the Subscription to be fair and reasonable and in the best interests of the Independent Shareholders and the Company as a whole. Accordingly, the Independent Directors unanimously recommend that the Independent Shareholders vote in favour of the Waiver Resolution to be proposed at the General Meeting.\nIn providing advice to the Independent Directors, Peel Hunt has taken into account the Independent Directors' commercial assessments, including in relation to the position and prospects of the Company in the event that the Subscription is not completed, as well as the confirmations of AOP's future intentions expressed in paragraph 5 above.\nThe Independent Directors who hold Ordinary Shares have irrevocably undertaken to vote in favour of all Resolutions in respect of their own shareholdings amounting to 5,959,728 Existing Ordinary Shares (representing 0.8 per cent. of the Existing Ordinary Shares in issue).\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\n+44 (0) 191 511 8500\nNominated Adviser, Financial Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Rory Sale/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/FeRACCRU\u00ae, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout\u00a0Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\u00a0The Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU\u00ae is commercialized in the\u00a0UK and European Union\u00a0by\u00a0Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with\u00a0Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR\u00ae/ FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with\u00a0Korea Pharma Co., Ltd.\u00a0for the Republic of Korea, and with\u00a0KYE Pharmaceuticals Inc.\u00a0for Canada.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\u00a0until the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nForward-Looking Statements\nThis press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the commercial strategy for ACCRUFeR\u00ae/FeRACCRU\u00ae. These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results and performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with the Company's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Company disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause its views to change.\nADMISSION STATISTICS\nSUBSCRIPTION AND RETAILBOOK OFFER STATISTICS(1)\nIssue Price\n3.0 pence\nIssue Price premium to closing middle market price of an Ordinary Share on the Disclosure Date\n5.3%\nNumber of Existing Ordinary Shares\n782,056,367\nNumber of Subscription Shares\n256,410,256\nMaximum number of RetailBook Offer Shares\n33,333,333\nSubscription Shares as a percentage of Existing Ordinary Shares\n32.79%\nMaximum number of RetailBook Offer Shares as a percentage of Existing Ordinary Shares\n4.26%\nPercentage of Existing Ordinary Shares held by AOP only as at the date of this announcement\n(2)\n39.84%\nPercentage of Existing Ordinary Shares held by AOP and its concert parties as at the date of this announcement\n41.93%\nEnlarged Share Capital following Subscription Admission and RetailBook Admission assuming the maximum number of RetailBook Offer Shares are issued\n1,071,799,957\nPercentage of the Enlarged Share Capital held by AOP only following completion of the Subscription assuming the maximum number of RetailBook Offer Shares are issued\n(2)\n53.00%\nPercentage of the Enlarged Share Capital held by AOP only following completion of the Subscription assuming no RetailBook Offer Shares are issued(2)\n54.70%\nPercentage of the Enlarged Share Capital held by AOP and its concert parties following completion of the Subscription assuming the maximum number of RetailBook Offer Shares are issued\n54.51%\nPercentage of the Enlarged Share Capital held by AOP and its concert parties following completion of the Subscription assuming no RetailBook Offer Shares are issued\n56.26%\nGross proceeds of the Subscription\n(3)\n$10,000,000\nMaximum gross proceeds of the RetailBook Offer\n\u00a31,000,000\nISIN of the Ordinary Shares\nGB00BYV81293\nLEI Number\n213800G74QWY15FC3W71\nNotes:\nAssuming the Resolutions are passed.\nExcluding AOP's concert parties.\nAt an exchange rate of USD 1.3:GBP 1 agreed between Shield and AOP.\nDEFINITIONS\nThe following definitions apply throughout this announcement, unless the context requires otherwise:\nacting in concert\nhas the definition given in the Takeover Code;\nAIM\nthe market of that name operated by the London Stock Exchange;\nAIM Rules\nthe AIM Rules for Companies published by the London Stock Exchange from time to time;\nAOP\nAOP Health International Management AG;\nAOP Austria\nAOP Orphan Pharmaceuticals GmbH;\nAOP Directors\nthe directors of AOP, from time to time;\nAOP Group\nAOP and its subsidiary undertakings, from time to time;\nArticles\nthe articles of association of the Company;\nCA 2006\nthe Companies Act 2006 as amended;\nCompany\nor Shield Shield Therapeutics plc, incorporated and registered in England and Wales (with registration number 09761509), whose registered office is at\nNorthern Design Centre Studio 6, 3rd Floor, Baltic Business Quarter, Gateshead Quays, England, NE8 3DF;\nconcert parties\npersons who are acting in concert as defined in the Takeover Code;\nCREST\nthe computerised settlement system (as defined in the CREST Regulations) operated by Euroclear which facilitates the holding and transfer of title to shares in uncertificated form;\nCREST Regulations\nthe Uncertificated Securities Regulations 2001 (SI 2001 No. 2001/3755) and any modification thereof or any regulations in substitution thereof for the time being in force;\nDirectors\nor Board the directors of the Company;\nDisclosure Date\n5 December 2024 being the latest practicable date prior to the publication of this announcement;\nEnlarged Share Capital\nthe issued ordinary share capital of the Company immediately following Subscription Admission and RetailBook Admission (comprising the Existing Ordinary Shares, the Subscription Shares and Issued RetailBook Offer Shares);\nEuroclear\nEuroclear UK & International Limited, the operator of CREST;\nExisting Ordinary Shares\nthe 782,056,367 Ordinary Shares in issue at the date of this announcement;\nFCA\nthe Financial Conduct Authority of the United Kingdom;\nForm of Proxy\nthe form of proxy for use by Shareholders in relation to the General Meeting;\nGeneral Meeting\nthe general meeting of the Company to be held at Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle NE8 3DF at 09:30 am on 24 December 2024, notice of which is set out at the end of the Circular;\nGroup\nthe Company and its subsidiaries and subsidiary undertakings;\nIndependent Directors\nthe Directors, other than Dr. Christian Schweiger and Dr. Rudolf Widmann;\nIndependent Shareholders\nthe Shareholders other than AOP and its concert parties;\nIrrevocable Undertakings\nthe irrevocable undertakings and consents received by the Company from the Directors and AOP to vote in favour of the Resolutions (excluding, in the case of Dr. Christian Schweiger, in relation to the Waiver Resolution)\nIssue Price\n3.0 pence per Ordinary Share;\nIssued RetailBook Offer Shares\nsuch number of RetailBook Offer Shares that are issued pursuant to the RetailBook Offer (if any);\nLondon Stock Exchange\nLondon Stock Exchange plc;\nMAR\nRegulation (EU) No.596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse including as it forms part of domestic law in the United Kingdom by virtue of the EUWA including by the Market Abuse (amendment) (EU Exit) Regulation 2019\n;\nOrdinary Shares\nordinary shares of 1.5 pence each in the capital of the Company;\nPanel\nthe UK Panel on Takeovers and Mergers;\nPanel Waiver\nthe waiver granted by the Panel (subject to the passing of the Waiver Resolution by the Independent Shareholders) in respect of an obligation of AOP and its concert parties (individually and collectively) to make a mandatory general offer pursuant to Rule 9 as a result of the issue of the Subscription Shares\nRelationship Agreement\nthe relationship agreement dated 4 May 2023 between AOP and the Company (as amended and restated from time to time), which regulates the relationship between AOP, as the Company\u2019s largest shareholder and the Company\nRegistrar\nLink Group;\nResolutions\nthe resolutions to be proposed at the General Meeting as set out in the notice of the General Meeting at the end of the Circular;\nRetailBook\nRetail Book Limited of 10 Queen Place, London, EC4R 1AG which is authorised and regulated by the Financial Conduct Authority (FRN: 99423) and is the retail capital markets platform undertaking the RetailBook Offer;\nRetailBook Admission\nadmission of the Issued RetailBook Offer Shares to trading on AIM becoming effective in accordance with Rule 6 of the AIM Rules;\nRetailBook Offer\nthe offer of up to 33,333,333 RetailBook Offer Shares on the terms of the RetailBook Offer Announcement;\nRetailBook Offer Announcement\nthe regulatory information service announcement issued by the Company dated 6 December 2024 in relation to the RetailBook Offer;\nRetailBook Offer Shares\nup to 33,333,333 new Ordinary Shares which the Company is proposing to offer to existing retail shareholders of the Company pursuant to the RetailBook Offer;\nRule 9\nRule 9 of the Takeover Code;\nSallyport\nSallyport Commercial Finance, LLC;\nShareholders\nholders of Ordinary Shares;\nShield US\nShield Therapeutics Inc., a company incorporated in Delaware and a wholly owned subsidiary of the Company;\nSTX UK\nShield TX (UK) Limited, a company incorporated in England and Wales under company number 06702064 and a wholly owned subsidiary of the Company;\nSubscription\nthe proposed subscription by AOP for the Subscription Shares at the Issue Price pursuant to the Subscription Agreement;\nSubscription Admission\nadmission of the Subscription Shares to trading on AIM becoming effective in accordance with Rule 6 of the AIM Rules;\nSubscription Agreement\nthe subscription agreement entered into between the Company and AOP on or about the date hereof in relation to the Subscription\nSubscription Shares\nthe 256,410,256 new Ordinary Shares which the Company is proposing to issue to AOP pursuant to the Subscription;\nsubsidiary\nand subsidiary have the meaning given to them in the CA 2006;\nundertakingSWK\nSWK Funding LLC;\nTakeover Code\nthe UK City Code on Takeovers and Mergers as issued, and as from time to time amended and interpreted by, the Panel;\nUK\nor United Kingdom the United Kingdom of Great Britain and Northern Ireland;\nUncertified\nor in uncertificated form recorded on the relevant register of the share\nor\nsecurity\u00a0concerned as being held in uncertified form in CREST and title to which, by virtue of the CREST Regulations, may be transferred by means of CREST;\nUS\nor United States the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia and all other areas subject to its jurisdiction; and\nWaiver Resolution\nthe ordinary resolution of the Independent Shareholders to approve the Panel Waiver to be proposed and held on a poll at the General Meeting which is set out in the notice of General Meeting at Resolution 1.\nUnless otherwise indicated, all references in the is announcement to \"GBP\" \"\u00a3\", \"pounds sterling\", \"sterling\", \"pence\" or \"p\" are to the lawful currency of the United Kingdom and all references to \"$\", \"US$\", \"USD\" or \"US dollars\" are to the lawful currency of the United States.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCUPGRUPUPCGGQ"
        },
        {
          "title": "Unaudited full year trading update",
          "announcement_date": "5th Feb 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "5 Feb 2025 07:00\nRNS Number : 8925V\nShield Therapeutics PLC\n05 February 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nUnaudited full year trading update\nGroup revenues ahead of expectations at $32.2m with ACCRUFeR\u00ae revenues growing 153% to $29.3m\n42% increase in net selling price to $237 per prescription in Q4 2024\nRemains on track to be cash flow positive by end of 2025\nLondon, UK, 5 February 2025:\nShield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specializing in iron deficiency, provides an unaudited full year\u00a0trading update for the year ended 31 December 2024 (\"FY24\").\nThis period reflects a significant step-up in revenue, alongside successfully streamlining the cost base and strengthening the Company's balance sheet. These initiatives are part of the Company's ongoing strategy to become cash flow positive by the end of calendar 2025\n.\nThe Company expects to report total revenues of $32.2m for FY24 (FY23: $17.5m revenues and other income) and has seen strong improvements in ACCRUFeR\u00ae prescriptions with 95% growth in total prescriptions to c.150,000 in 2024 generating $29.3m of ACCRUFeR\u00ae revenues (FY23: $11.6m), an increase of 153%.\nDuring the final quarter of 2024, the Company took a decisive step to strengthen its balance sheet by securing $10.0m in equity funding from its largest shareholder AOP Health International Management AG (\"AOP\"), alongside a small contribution from a RetailBook Offer. This funding, which was completed at a premium to the prevailing share price, was received in January 2025. Shield therefore held cash and cash equivalents of $6.5m as of 31 December 2024 (31 December 2023 was $13.9m), with an additional $10m of gross proceeds received on 3 January 2025. The strengthened balance sheet, along with the previously announced savings to the Group's operating cost base, will help the Company achieve its aim of becoming cash flow positive by the end of calendar 2025.\nQ4 2024 Key Business Metrics:\n\u00b7\nStrong US ACCRUFeR\u00ae revenue\n:\u00a0$11.2m, showing a 56% growth over $7.2m in Q3 2024\n\u00b7\n42% higher average ACCRUFeR\u00ae net selling price:\n$237\u00a0per prescription compared to $167 in Q3 2024, driven primarily by the impact of pricing changes implemented within the consignment business\n\u00b7\nTotal Q4 Prescriptions:\nc.41,000, with only 22% consignment-based prescriptions that were dispensed at a significantly subsidized price to patients and were not reimbursed by payors, compared to 37% in Q3 2024. This reduction also helped achieve a higher average net selling price in the quarter\n\u00b7\nCash and cash equivalents\n: $6.5m as of 31 December 2024, with an additional $10.0m of gross proceeds received post year end, providing sufficient capital to allow the Company to become cash flow positive by the end of the year. Shield's rate of cash burn remains highly dependent on the rate of sales growth for ACCRUFeR\u00ae\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"\nWe have made significant efforts to streamline our cost base whilst driving growth in ACCRUFeR\u00ae revenues, prescriptions, and average net price, all in pursuit of achieving positive cash flow by the end of the calendar year. I am especially encouraged by the strong revenue momentum, as our team, in close collaboration with our partner Viatris, work diligently to expand our presence in the US market and position ACCRUFeR\u00ae as the therapy of choice.\n\"\nInvestor presentation\nCEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the unaudited full year trading update via the Investor Meet Company platform at\u00a02.00pm\u00a0(GMT) on Thursday 6 February 2025.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am (GMT) or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet\u00a0Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow\u00a0Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\n+44 (0) 191 511 8500\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\ninvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel / Patrick Birkholm\n+44 (0)20 7418 8900\nJoint Broker\n+44 (0)20 7220 0500\nCavendish Ltd\nGeoff Nash / Rory Sale / Nigel Birks / Harriet Ward\nFinancial PR & IR Advisor\nWalbrook PR\nAlice Woodings / Lianne Applegarth\n+44 (0)20 7933 8780 or\nshield@walbrookpr.com\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris Inc. Outside of the U.S., the Company licensed the rights to four specialty pharmaceutical companies. FeRACCRU\u00ae is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR\u00ae/ FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with KYE Pharmaceuticals Inc. for Canada.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTFLFLEFVISIIE"
        },
        {
          "title": "ACCRUFeR\u00ae assigned Priority Review in US by FDA",
          "announcement_date": "4th Sep 2025",
          "release_time": "7:03 am",
          "source": "RNS",
          "content": "4 Sep 2025 07:03\nRNS Number : 9329X\nShield Therapeutics PLC\n04 September 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nACCRUFeR\u00ae assigned Priority Review in the US by FDA in children with iron deficiency anemia (IDA)\nPending successful review, approval in the US is anticipated in 2026\nLondon, UK, September 4, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA) has accepted ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) as a Clinical Supplement and assigned Priority Review to extend the indication for ACCRUFeR\u00ae/FeRACCRU\u00ae to include adolescents aged 10 years and above.\nFollowing the positive results from the Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that confirmed the efficacy, safety, and tolerability of the new oral liquid pediatric formulation in children with (IDA), Shield submitted a clinical supplement application to the FDA in June 2025 for the approval of ACCRUFeR\u00ae/FeRACCRU\u00ae in the pediatric population. FDA has granted Priority Review for the supplement as it supports the extension of the label to a pediatric population based on a final agreed pediatric study report. Pending successful review, approval is anticipated in 2026.\nShield plans to file for a further extension of the indication to include children 1 month and above in conjunction with the submission of an NDA for a new pediatric formulation (ferric maltol suspension) which was used in the successful FORTIS Phase 3 study in this population. If approved, this formulation may also offer an alternative approach for adults who can't swallow our current capsule formulation.\nShield's licensing partner in the EU, Norgine B.V., also filed a regulatory submission to the EMA in Q2 2025 for the approval of\nFeRACCRU\n\u00ae (ferric maltol) in the adolescent population. Pending successful review, approval is also anticipated in 2026.\nDr Jackie Mitchell, VP of Quality, RA and Clinical Development at Shield, commented:\n\"\nWe are delighted to be able to progress a further significant expansion of the patient population to adolescents, who can benefit from a much needed safe and effective oral iron treatment.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients.\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nDetails of the FORTIS/ST10-01-305 Phase 3 study\nThe open label randomized Phase 3 study included children aged 1 month to 17 years with mild to moderate IDA, who also had serum ferritin levels below 30 \u03bcg/L or ferritin levels below 50 \u03bcg/L and transferrin saturation below 20%. Children aged 2 to 17 years were randomized 1:1 to receive either ferric maltol (N=31) or ferrous sulphate (N = 30). Children 1 months to under 2 years (N=4) were all assigned to receive ferric maltol treatment.\nThe full data sets, including secondary endpoints and pharmacokinetic (PK) sub-study parameters, will be submitted for peer-review and subsequent presentation/publication.\nThe trial is the final study in the comprehensive pediatric development program that Shield committed to implement with both the European EMA and the US FDA.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCZZGGLGFLGKZZ"
        }
      ],
      "themes": [
        "drilling"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 125,
      "sentiment_breakdown": {
        "positive": 16.0,
        "neutral": 84.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "TOPPED_OUT"
    },
    "volatility": {
      "atr_normalized": 8.18,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2025-12-03"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "INDUSTRIALS",
      "name": "Industrials",
      "icon": "\ud83c\udfed",
      "color": "#64748b",
      "crash_patterns": [
        "Order book decline or cancellations",
        "Margin compression (input costs)",
        "Cyclical demand weakness",
        "Project delays or overruns",
        "Working capital strain"
      ],
      "recovery_paths": [
        "Order book growth or new contracts",
        "Margin recovery (efficiency gains)",
        "Cyclical upturn (capex recovery)",
        "M&A consolidation",
        "Product innovation or new markets"
      ],
      "active_patterns": [
        "Order book decline or cancellations",
        "Project delays or overruns"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Order book value (forward revenue)",
        "Book-to-bill ratio",
        "Operating margin trends",
        "Working capital efficiency",
        "Capex cycles (customer industries)"
      ]
    },
    "panic_analysis": {
      "panic_score": 70,
      "signal": "HIGH_PANIC",
      "interpretation": "\ud83d\udfe0 Fear dominant - watch for reversal signs",
      "breakdown": {
        "price_destruction": 40,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 40/40 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 638% proven capacity"
      ],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "HIGH_PANIC",
        "icon": "\ud83d\udfe0",
        "text": "Fear 70/100",
        "color": "#f59e0b"
      },
      {
        "type": "CROWDED",
        "icon": "\u26a0\ufe0f",
        "text": "Crowded",
        "color": "#f59e0b"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 60",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "ACCRUFeR receives Authorisation by Korean Ministry",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "RetailBook Offer",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Subscription by AOP Health to raise US$10 million",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Unaudited full year trading update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "ACCRUFeR\u00ae assigned Priority Review in US by FDA",
        "status": "published",
        "icon": "\ud83d\udce2"
      }
    ],
    "decision_matrix": {
      "decision": "AVOID",
      "reason": "\u274c SELL/TAKE_PROFITS - timing CROWDED",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "70/100",
          "pass": true,
          "icon": "\ud83d\udd34"
        },
        {
          "criterion": "Timing Regime",
          "value": "CROWDED",
          "pass": false,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "60/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "2 active",
          "pass": true,
          "icon": "\ud83c\udfed"
        }
      ],
      "pass_rate": "4/5"
    },
    "contrarian_panic": {
      "total_score": 47,
      "band": "\ud83d\udfe1 MODERATE COMPRESSION (Top 30% - GOOD SETUP)",
      "components": {
        "compression": {
          "score": 22,
          "max": 40,
          "signals_30d": 1,
          "signals_60d": 1,
          "signals_90d": 7,
          "signals_per_week": 0.54,
          "total_signals": 28,
          "rsi_extreme_count": 4,
          "rsi_ultra_count": 3,
          "escalation_count": 1,
          "density_score": 8,
          "rsi_score": 10,
          "escalation_score": 4,
          "description": "0.5 signals/week | 4 RSI<20 | 1 escalations | \ud83d\udcca MODERATE COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.03,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 15,
          "max": 15,
          "best_historical_rally": 863.3,
          "avg_rally": 382.6,
          "signal_count": 28,
          "description": "BIG POPPER - Historical 5x+ (863%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation"
        }
      },
      "ticker": "STX.L",
      "signal_date": "2024-07-15",
      "total_signals_history": 28
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=87.5%)",
      "Volume confirmation: +10 (Relative_Volume=2.0)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +16 (best_rally_pct=638%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 87.55,
      "reason": "Drawdown of 87.5% gives 18/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.03,
      "reason": "Relative volume 2.03x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 16,
      "best_rally_pct": 637.5,
      "reason": "Best rally of 638% gives 16/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Historically strong runner - massive upside when it moves",
        "tag": "HIGH",
        "evidence": [
          "best_rally_pct=638%",
          "Rally_Count=1.0"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2024-07-15"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Active trade",
      "action": "SELL/TAKE_PROFITS",
      "sizing": "1-3% position based on conviction",
      "risk": "Stop below recent support / invalidation level",
      "profit_taking": "Scale out into strength: 25% @ +15%, 50% @ +50%, trail runner"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "CROWDED",
    "run_multiple": 1.0,
    "current_run_pct": 634.75,
    "avg_historical_run_pct": 637.5
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows CROWDED timing with 60/100 APEX score. Historical data shows 1 rallies averaging 638% upside. Current position: +634.8%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Strong historical rally behavior (638% best run)"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Late stage. Consider taking profits as risk/reward deteriorates.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}